文献速递心律失常

体内碱基编辑修复Scn5a基因挽救3型长QT综合征小鼠

In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice.
PubMed 文献 · Circulation · 2023-11-15

该研究在携带SCN5A T1307M致病变异的3型长QT综合征小鼠模型中,采用AAV9递送分裂型腺嘌呤碱基编辑器ABEmax进行在体编辑。单次腹腔注射后最高99.20%的Scn5a转录本被纠正,纠正率>60%可消除QT延长,且未检测到脱靶DNA或RNA编辑事件。

要点

  • AAV9-ABEmax在体编辑可纠正Scn5a T1307M变异,最高纠正率达99.20%。
  • Scn5a mRNA纠正率>60%可消除QT延长,<60%仅减轻QT延长。
  • 未检测到脱靶DNA或RNA编辑事件,部分纠正所致心肌细胞异质性未诱发严重心律失常。

核心结论

  • 体内AAV9-ABEmax碱基编辑可纠正变异Scn5a等位基因,有效改善心律失常表型,为遗传性心律失常治疗提供概念验证。

研究设计与样本

  • 研究通过将T1307M致病变异引入Scn5a基因构建3型长QT综合征小鼠模型,采用分裂为两部分的腺嘌呤碱基编辑器经AAV9-ABEmax递送至心脏。

主要发现

  • 纯合与杂合T1307M小鼠均出现显著QT延长。
  • 卡巴胆碱给药可诱发纯合T1307M小鼠(20%)尖端扭转型室速或室性心动过速,杂合与野生型小鼠未见。
  • 出生后第14天单次腹腔注射AAV9-ABEmax后,T1307M小鼠中最高99.20%的Scn5a转录本被纠正。
  • Scn5a mRNA纠正率>60%消除QT延长,<60%减轻QT延长。
  • 部分Scn5a纠正导致心肌细胞异质性,但未诱发严重心律失常,且未检测到脱靶DNA或RNA编辑事件。

临床怎么用

  • 该研究为遗传性心律失常的在体碱基编辑治疗提供概念验证,提示纠正率>60%可能是消除QT延长的关键阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pathogenic variants in SCN5A can result in long QT syndrome type 3, a life-threatening genetic disease. Adenine base editors can convert targeted A T base pairs to G C base pairs, offering a promising tool to correct pathogenic variants. METHODS: We generated a long QT syndrome type 3 mouse model by introducing the T1307M pathogenic variant into the Scn5a gene. The adenine base editor was split into 2 smaller parts and delivered into the heart by adeno-associated virus serotype 9 (AAV9-ABEmax) to correct the T1307M pathogenic variant. RESULTS: Both homozygous and heterozygous T1307M mice showed significant QT prolongation. Carbachol administration induced Torsades de Pointes or ventricular tachycardia for homozygous T1307M mice (20%) but not for heterozygous or wild-type mice. A single intraperitoneal injection of AAV9-ABEmax at postnatal day 14 resulted in up to 99.20% Scn5a transcripts corrected in T1307M mice. Scn5a mRNA correction rate >60% eliminated QT prolongation; Scn5a mRNA correction rate <60% alleviated QT prolongation. Partial Scn5a correction resulted in cardiomyocytes heterogeneity, which did not induce severe arrhythmias. We did not detect off-target DNA or RNA editing events in ABEmax-treated mouse hearts. CONCLUSIONS: These findings show that in vivo AAV9-ABEmax editing can correct the variant Scn5a allele, effectively ameliorating arrhythmia phenotypes. Our results offer a proof of concept for the treatment of hereditary arrhythmias.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Qi M, Ma S, Liu J, et al. In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice. Circulation. 2023. PMID: 37965733. doi:10.1161/CIRCULATIONAHA.123.065624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。